FDA Regulation of Stem Cell Therapies. Regulation of adipose derived stromal preps
|
|
- Anabel Fletcher
- 5 years ago
- Views:
Transcription
1 2018 FDA Regulation of Stem Cell Therapies Regulation of adipose derived stromal preps
2 EMERGING NEW FIELD BUT STILL A TODDLER Regenerative medicine technologies for orthopedic medicine application has produced basic science and clinical research in investigating the use of stem cells in several areas including, but not limited to: Osteoarthritis 1,2 Articular cartilage repair 3,4 Anterior cruciate ligament (ACL) reconstruction 5 8 Tendon healing 9 12 Meniscus regeneration 13 15
3 References Koh YG, Choi YJ, Kwon OR, Kim YS. Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees. Am J Sports Med 2014;42(7): Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 2014;32(5): Anderson JA, Little D, Toth AP, et al. Stem cell therapies for knee cartilage repair: the current status
4 NEW UPDATES ON FDA GUIDELINES Recent FDA documents released over 2 years: CURES Act: Act passed to give FDA guidance. Important part of reg process. FDA has guidance documents. But as we all know, guidance documents are not binding, therefore, are often left to interpretation. This is as a draft form but there are no requirements to issue final document. FDA is supposed to promote: SAFETY INNOVATION Mary Ann Chirba, JD, DSc, MPH
5 Current Good Tissue Practice CGTP Facilities CGTP: CGMPs provide for systems that assure proper design, monitoring and control of manufacturing processes and facilities. Supplies Environment Labeling CGMP Flexible to implement best controls and to allow companies to use current up-to-date technologies. Equipment Storage Donors Distribution
6 FDA REGULATION Love / Hate Relationships Everything that the FDA does should be consistent with these goals. We should NOT be anti-regulation. FDA needs to be faithful to regulations and so do we. We are going to have to learn to steer through this land mine of reg requirements and we CANNOT do this alone. Many of us are silo ed in our private practices and many are trying to come into compliance. What has brought this on. BAD ACTORS
7 FDA Power to Regulate FDA REGULATES CELL & TISSUE PRODUCTS AS PART OF ITS IMPLEMENTATION OF 2 FEDERAL LAWS: FDCA Food, Drug & Cosmetics Act (FDCA, drugs & devices) Public Health & Service Act (PHSA biologics) REGULATION: Can issue draft guidance documents but not required to issue final document. Not required to reply to comments and recommendations. CURES Act requires the FDA to issue guidance documents. They can do this with no obligation to finalize the document and thus can leave it in limbo.
8 Tiered Risk: FDA took a tiered risk approach, to improve health and safety concerns: Communicable disease transmission Unsafe practices Ineffective products, etc. The tiered, risk-based approach is contained in a set of regulations commonly referred to as the tissue rules.
9 Use OF HTCP TISSUES AND CELLS 21 CFR Arose from organ transplants. Sets out the legal framework for manufacturers of Human Cells, Tissue, and Cellular and Tissue based products (HCT/P). An adult stem cell also falls within the FDCA s definition of a drug because it is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease and intended to affect the structure or function of the body.
10 21 CFR Definitions MAY BE GOOD AT END ADDED Indicates that bone marrow and whole blood are not HCT/Ps Except for vascularized organs, some reproductive materials, etc. Adipose tissue at this point is an HCT/P.
11 21 CFR (d) HCT/Ps: Human cells, tissues, cellular or tissue-based products = HCT/Ps. Articles containing bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic/progenitor cells derived from peripheral and cord blood, manipulated autologous chondrocytes, epithelial cells on a synthetic matrix, semen and other reproductive tissue.
12 Role of 21 CFR (d) cont. The following articles are not considered HCT/Ps: Whole blood or blood components or blood derivative products subject to listing under part 607 and 207 respectively. Minimally manipulated bone marrow for homologous use and not combined with other articles (except for water, crystalloids, or a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the bone marrow.
13 Blood & Bone Marrow dodged the bullet How did bone marrow and blood get by the FDA? Something cannot be regulated by 2 federal agencies at the same time. Bone marrow and blood are regulated by different federal agencies than the FDA. They had to carve this out is a law and they would have to change the law. Therefore bone marrow and blood, can be exempt so long as you remain compliant with homologous use and other FDA regulations such as culture and expansion, etc. In Europe, it is possible that bone marrow and blood will be considered a drug in the near future.
14 Do s & Don ts DO S AND DON Ts for minimal manipulation: Cutting, sizing, shaping, cleansing are okay for the most part. Physically altering the characteristics of the structural tissue/cell away from or how it is found in the body is not OK. Destroying the structure of the fat tissue to acquire MSCs NO WE WILL LOOSE THIS UNLESS Culture and expansion of cells NO
15 Homologous use origin BMAC: Many cells that serve no function in the tissues where are injecting. However, MSCs mobilize from marrow and can be found in soft tissues, etc. We are placing specific cells contained within bone marrow into tissues that also have the same cells. Homologous use? Probably. Injection of same cells into the IV for systemic use or systemic effect. NOT hom. use!!!
16 Homologous use continued You need to have one or more functions of bone marrow (1271) not all the same functions as bone marrow. Since the MSCs can be found in the periphery serving a regenerative function, secretion of regulatory proteins, etc. we will continue to stick with this argument. So far, so good.
17 Do s & Don ts for homologous use: Saphenous vein graft to transplant to another location in the body. Yes Extract, fat, wash it and use it as a graft for subcutaneous injection in the face or hand. Yes Place that same fat in breast NO You cannot digest fat or process it to release cells (SVF) for use as a treatment. AFG intra-articular: We will loose this tool because of homologous use definition. STRUCTURAL TISSUE
18 Mixing You can mix certain things ie; saline, etc. You cannot mix other articles that would have a biologic effect on the cells. At point of service, some believe you can mix such as PRP and BMAC. Others do not believe you can and state the injections, if you are going to use other products, need to be done separately.
19 21 CFR (b) A little somethings extra part (b) If you are a domestic or foreign establishment that manufactures an HCT/P described in paragraph (a) of this section: 1. You must register with the FDA. 2. You must submit to FDA list of each HCT/P, manufactured. 3. You must comply with other requirements contained in this part. Some believe if you are using these products you are an extension of the manufacture, and you need to register?
20 21 CFR (b) (b) You are not required to comply with the requirements of this part if you are an establishment that removes HCT/Ps from individual implants such HCT/Ps into the same individual during the same surgical procedure. This has been subject to interpretation, used and abused. You have to have a quality system, you can be audited, records, etc. 15(b) allows you not to have to register.
21 The odd thing You are the manufacturer when you acquire and process cells. When you are in the OR or procedure suite with the syringe and needle in your hand you are the physician in the practice of medicine. The land mines
22 What we have been living with FDA draft guidance doc 2014 Oct same surgical procedure. FDA draft guidance doc 2014 dec adipose tissue. FDA draft guidance doc 2015 minimal manip. FDA draft guidance doc 2015 homogous use. Draft guidance: do not have legal authority. There is no precedent established and these drafts are purely advisory. This has been the problem. We have DC d SVF and mourn it s loss.
23 Now we have the guidance doc It does not change a word in The regulatory framework will not be altered BUT You will now have a better understanding We understand better homologous use. We understand better use of adipose tissue and AFGs and SVF. It is not that this does not work
24 3 Catagories of HCTP s No special HCTP Oversight under FDCA Essentially not regarded as GCTP Whole blood, blood derived products Minimal Oversight under PHSA 361 Greater Oversight under PHSA 351 HTCP s are a hybrid and thus can fall into one category, 2 or all 3 catagories. This is where we can get into trouble. What I am frustrated with is how do I REASONABLY come under compliance and pray that they do not destroy this
25 42 U.S.C. 262 (i)(1) An adult stem cell is a biological product under the PHSA because like a therapeutic serum, blood, blood component or derivative, protein or analogous product, it is applicable to prevention, treatment or cure of a disease or condition in human beings. Ok SO FAR : )
26 4 Key Terms: MANURACTURER: A physician becomes a manufacturer of HCT/Ps by engaging in any or all steps in HCT/P recovery, processing, storage, labeling, packaging, or distribution. ESTABLISHMENT: AN establishment is a physician s office, clinic, or any place of business under one management that manufactures HCT/Ps. COMBINING: Combining HCT/Ps with other articles can increase safety concerns and thereby increase the degree of regulatory oversight. REGULATIONS THUS EXEMPT COMBINATION OF HCT/P with water, crystalloids, or a sterilizing, preserving, or storage agent, provided that their addition poses no additional concerns regarding clinical safety.
27 MINIMAL MINIPULATION. THE NEMESIS Minimal Manipulation. The regulation defines it separately for structural tissue and cells nonstructural tissues both are relevant TO ORTHOPEDIC MEDICINE PRACTICE medicine although manipulation of cells and nonstructural tissues is the focus of this discussion. Structural tissue: adipose tissue, bone, cartilage, etc. Non structural tissue: blood, bone marrow blood, fluids 21 CFR
28 Minimal Manipulation Minimal Manipulation. The regulation defines it separately for structural tissue and cells nonstructural tissues both are relevant TO ORTHOPEDIC MEDICINE PRACTICE medicine although manipulation of cells and nonstructural tissues is the focus of this discussion. Structural tissue: adipose tissue, bone, cartilage, etc. Non structural tissue: blood, bone marrow blood, fluids
29 Minimal manipulation cont. For structural tissue minimal manipulation involves processing of the HCT/P that does not alter the original relevant characteristics of the tissue relating to the tissue s utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, minimal manipulation is processing of the HCT/P that does not alter the relevant biological characteristics of cells or tissues. The degree of cell manipulation is critical in determining where an HCT/P will fall in the following three-tiered framework. ü ü ü Category 1: No HCT/P Oversight Category 2: Section 361 Products with Minimal Oversight Category 3: Section 351 s Extensive Regulation of HCT/Ps as Biologics and Drugs
30 Lets look at these 3 important categories. Category 1: No HCT/P Oversight 21 CFR Products in this category are not regulated as HCT/Ps because they are deemed to be of low risk. Category 1 includes vascularized human organs for transplantation, whole blood and blood-derived products, and extracted human products such as collagen and bone marrow that are minimally manipulated, for homologous use and not combined with another article (except for the purpose of sterilizing, preserving, or storing). By default, Category 1 also includes cells that are expressly exempted from Categories 2 and 3, described later.
31 Category 1: No HCT/P Oversight CFR. For us: exemption covers an establishment that removes HCT/Ps from an individual and implants such HCT/Ps into the same individual during the same surgical procedure 21 CFR (b) NOTE: This is only if minimally manipulated & complies to homologous use Regs. Not combined with other articles. We must comply with cgtps
32 Category 2: Section 361 Products with Minimal Oversight The FDA views Section 361 products as posing a greater risk with regard to safety and regulates them more extensively to prevent contamination, infection, and disease transmission. Section 361 products that are commonly used in sports medicine include bone, cartilage, ligament, tendon, and skin. 21 CFR To fall within Section 361, these products must be: No more than minimally manipulated which, again, for structural tissue, means preserving the original relevant characteristics of the tissue relating to the tissue s utility for reconstruction, repair, or replacement and for cells or nonstructural tissues, prevents a change in the relevant biological characteristics of cells or tissues during processing, storage, etc. 21 CFR
33 Category 2: Section 361 Products with Minimal Oversight Combined with no other cells, tissues, or articles except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that their addition poses no additional concerns regarding clinical safety. 4. These products must also have either a. No systemic effect or otherwise depend on the metabolic activity of living cells for their primary function or BIO D example b. A systemic effect or depend on the metabolic and for activity of living cells for their primary function, i. Autologous use
34 Bio-D: sold sheets of amnionic membrane for wound cover. Approved Then they said it HELPS the wound heal faster. NO, non homologous use and they Got a letter from the FDA!!!
35 Category 2: Section 361 For cells and nonstructural tissues, certain methods have been expressly characterized as minimal manipulation; that is, as involving no change in cell function or characteristics during processing, storage, and the like. They include the following: Centrifugation Cutting, grinding, or shaping Soaking in antibiotic solution Sterilization by ethylene oxide treatment or irradiation Cell separation Lyophilization Cryopreservation or freezing
36 Category 2: Section 361 Physicians who use or manufacture Section 361 HCT/Ps must employ cgtps, register their office or clinic as an establishment, and submit an annually updated list of each HCT/P manufactured to CBER.30,31 They need not obtain premarketing approval before using the product or follow current Good Manufacturing Practices (cgmps) in preparing them.
37 Category 3: Section 351 s Extensive Regulation of HCT/Ps as Biologics and Drugs Products are most likely to shift from the comparatively relaxed oversight of Section 361 to the more stringent requirements of Section 351 if at least in the FDA s view they present greater risks. While Section 361 focuses on safety and preventing infection and disease transmission, Section 351 concentrates on both safety and effectiveness. For the clinician, this imposes more onerous requirements (such as cgmps and premarketing approval) with little distinction between individuals and small physician practices versus larger pharmaceutical industries. Thus, cells or processing methods that fail to satisfy any of Section 361 s requirements will cast a product into the heavily regulated
38 Category 3: Section 351 s Extensive Regulation Section 351 track A product will fall within Section 351 if more of the following: it is one or More than minimally manipulated, which for cells and nonstructural tissue means to present a risk of change in cell morphology, function, expression, or other relevant biological characteristics during processing, storage, etc. Used for a nonhomologous purpose. 3. Combined with other articles that may pose additional concerns regarding clinical safety. 3. Have a systemic effect or otherwise rely on the metabolic activity of living cells for its primary function, and be used in a context other than autologous use, allogeneic use in a first or second degree
39 Compliance with 351 Section 351: Must register and file list of hct/p requires to list and file each HCT/Ps with CBER each year. Must obtainin formal premarket approval from the FDA. This can involve submitting a IND!!! an Investigational New Drug Application, Biologics License Application, or, when dealing with a Section 501k medical device, a premarket approval application or premarket notification. Costly and time-consuming controlled trials to establish product safety, purity, potency, efficacy, and stability. Also must follow GMP standards which includes Rx prescription drug labeling requirements similar to major pharma. Without this product will be considered adulterated and /or misbranded. as per fdca and phsa. This is true even using autologous cell preps!!!
40 Office based gmp? It may be possible It will be expensive
41 351 vs 361 It must be emphasized that Section 351 applies equally to autologous and allogeneic use in contrast to Section 361, which treats autologous and allogeneic use differently. Consequently, treating a patient with a Section 351 HCT/P means that the physician as manufacturer and the office, clinic, or hospital as establishment are marketing the cell product. Treatment of this kind requires premarket approval even if those cells are to be injected into the same patient from which they were harvested.
42 Navigating the mine field of regulations Determining which regulatory track applies is also difficult because as therapies evolve and technologies improve, definitional ambiguities remain unresolved. In this respect, one of the most difficult challenges is defining what qualifies as minimal versus more than minimal manipulation. This is a key factor in 351 or 361. determining
43 CASE EXAMPLES
44 Intraoperative Isolation of Autologous Bone Marrow Derived Stem Cells by Centrifugation and Injection This is likely to qualify as a Category 1 non-hct/p because the cell product involves a specifically exempted product (bone marrow Is autologous, used for a homologous purpose, and not combined with other articles. Moreover, the FDA has long viewed centrifugation as minimal manipulation. Recent draft guidances,35 37 however, Still some questions exist and ambiguous wording in draft guidelines will be clarified to characterize centrifugation and other means of isolation as it pertains to MM.
45 INTRA OPERATIVE BMAC cont. In this case probably exempt under cat 1. Will probably not have to comply with 351 and file HCT/Ps w/ CBE and provide annual reports, etc. Will not need to file under 361.
46 INTRAOPERATIVE SVF BY CENTRIFUCATION 1. Current regulations treat stem cells derived from bone marrow and fat differently. Bone marrow derived stem cells explicitly qualify as Category 1/nonHCT/Ps but only if they are for autologous and homologous use, minimally manipulated, not combined with articles that raise safety concerns, and have no systemic effect. Adipose tissue derived stem cells are not expressly exempted and, therefore, are typically regulated as Category 2/Section 361 or Category 3/Section 351 products depending on the level of manipulation, intended use, etc. A recent draft guidance would subject adipose stem cells, which are obviously cellular, to the structural as opposed to cellular definition of minimal manipulation. 1-3 FDA. Minimal Manipulation of Human Cells, Tissues and Cellular and
47 Intra-op SVF by centrifugation Adipose tissue derived stem cells are not expressly exempted and, therefore, are typically regulated as Category 2 / Section 361 or Category 3 / Section 351 products depending on the level of manipulation, intended use, etc. This immediately incited a broad array of concerns among clinicians that may sway the FDA to alter its position.
48 Intra-op SVF by centrifugation The scenario described here, however, should involve the kind of same surgical procedure that is exempt from Sections 361 and 351 because we feel so long as it is : Same day Autologous, homologous, qualified for minimal manipulation Harvested, processed and reinjected without interruption of the overall process BUT, based on new draft fda will need to clarify or dismiss its recent draft guidance. a question could be raised as to whether using an adipocyte technically qualifies as homologous use as the cell source fat arguably has little to do with the object of repair. To date, this has not been a regulatory focus but the FDA has signaled that it will examine this more closely.
49 Intra-op SVF by centrifugation For now, this procedure would most likely fall within Category 1 s same surgical procedure exemption as the cells are withdrawn, centrifuged, separated, and reinjected into the same patient, and completed within the same room during a time frame of several hours. Under Category 1, the treatment could go forward with no need to register the establishment, submit lists of HCT/Ps, obtain premarket approval or follow manufacturing or labeling requirements.
50 Examples 1. Isolation by centrifugation
51 Worst case scenario At most, it is likely to fall within Category 2 s relatively minimal Section 361 oversight as cell separation is accomplished through centrifugation, a form of minimal manipulation, and the resulting product will be used autologously. Should Section 361 control, the physician as manufacturer would need to register the office, clinic, or hospital as an establishment with CBER, and also provide CBER with an annually updated list of all HCT/Ps used at that establishment.
52 Intraoperative Selective Isolation of Adipose- Derived Stem Cells through Treatment of the Stromal-Vascular Fraction with Collagenase and Albumin and Injection Collagenase produces a higher yield of MSC We were previously stating that FDA has not formally defined whether or not this constitutes more than minimal manipulation. Several agency warnings and nonbinding guidance documents issued by the FDA indicate that introducing an enzyme to increase yield may qualify as more than minimal manipulation as it may pose a risk of changing cell behavior or characteristics. Now we know this is not disallowed
53 I am going to continue until they stop me
54 Enzymatic SVF..IF IF if We hope!!!!!! if not cat 1 that it will fall under cat 2 section 361: More than minimal manipulation Requires registration and Hct/p listing with cber. If you decide that introduction of collagenase presents little risk to cell morphology and behavior, the fda has broad discretion to disagree. fda informal statements to date suggest that it will characterize SVF with collagenase as more than minimal manipulation, thereby triggering Category 3 s Section 351 requirements.
55 SVF. Slipping out of our control What do we do?? Persuade the FDA to classify this or any specific procedure as minimal manipulation under Category 2/Section 361. The only remaining option is to abide by Section 351 and complete all of the following: Register with CBER Submit lists of HCT/Ps used to CBER Follow cgmps for pharmaceutical drugs Follow prescription drug labeling requirements 3. Undertake the time and obtaining premarket controlled expense involved in approval (including clinical trials)
56 If you do not comply 32 CFR Failing to satisfy any of these requirements will expose the physician and clinic: ü ü ü ü stiff sanctions site inspections permanent injunction shutdown of operations
57 Category 3: Section 351 s Extensive Regulation of HCT/Ps as Biologics and Drugs Section 361 focuses on safety and preventing infection and disease transmission. Section 351 concentrates on both safety and effectiveness. cgmps and premarketing approval
58 Reminder: 351 More than minimally manipulated, which for cells and nonstructural tissue means to present a risk of change in cell morphology, function, expression, or other relevant biological characteristics during processing, storage, etc. Used for a nonhomologous purpose. Combined with other articles that may pose additional concerns regarding clinical safety. Have a systemic effect or otherwise rely on the metabolic activity of living cells for its primary function, and be used in a context other than autologous use, allogeneic use in a first or second degree relative, or reproductive use.
59 2 more points on 351 Harvest of Cells in the United States with Culture, Expansion, and Delayed Injection Overseas Harvest here go over there. Will end up being a 351 under purview of fda Harvest of Cells there and inject there, will be out of jurisdiction of fda To be blunt, it makes no sense for the FDA to insist that a practicing physician
60 Thoughts: What ever the future holds for in office procedures to we will have losses and few gains. It will start to become more expensive and increase operational cost. We may have to have GMP labs WITHIN OUR OWN OFFICES!
61 Historical points in medicine 2000 BCE: Here, eat this root AD: That root is heathen. Here, say this prayer AD: That prayer is superstition. Here, drink this potion AD: That potion is snake oil. Here, swallow this pill AD: That pill is ineffective. Here, take this antibiotic AD: That antibiotic is artificial. Here, eat this root.
62 Historical points in orthopedic medicine 1950 Here lets inject with dextrose 1960 It hurts? Lets cut that out. 1970: Here take this opiod 1980: It hurts? I told you we should have cut that out. 1990: Surgery wont work go exercise 2000: Lets inject PRP 2010: Lets try stem cell injection 2015: Stem cell seems to be working lets mix all this together.
63 Not what but how
64 Thank you Michael N. Brown, MD
FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps
FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps September 27, 2018 Presentation by: Elaine H. Tseng Partner FDA and Life Sciences Group King & Spalding Discussion with: Thomas Poché Vice
More informationFDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies
FDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies Executive Summary, June 2015 Life Sciences Practice Group AUTHOR Areta L. Kupchyk Nixon Peabody LLP Washington,
More informationHCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
More information3/20/2017. R 3 Repair Paradigm REGENERATIVE MEDICINE GLOSSARY OF STEM CELL PLATFORMS. Limitations of Embryonic Stem Cells
R 3 Repair Paradigm CENTER FOR REGENERATIVE MEDICINE Regenerative Medicine Regulatory And Practice Management Focus Replacement ACL/UCL Reconstruction Regeneration Next generation therapy Repair Rejuvenation
More informationFDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)
FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach
More informationFDA Regulation of Adult Stem Cell Therapies as Used in Sports Medicine
Boston College Law School From the SelectedWorks of Mary Ann Chirba February, 2015 FDA Regulation of Adult Stem Cell Therapies as Used in Sports Medicine Mary Ann Chirba, Boston College Law School Berkly
More informationStem Cells, Regenerative Medicine and cgmp (GTP)
Stem Cells, Regenerative Medicine and cgmp (GTP) Encompass Stem cell based therapies activities Collection source Purification Isolation from other cell types if needed Manipulation Minimal vs Moderate
More informationPoint-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization.
Philadelphia, 2013 Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization. Brian Barnes, Ph.D. VP, Clinical and Regulatory Affairs
More information6/2/17. Updates on Regulatory Issues for Clinical Use of Biologics. Purpose. Biologics. Andrew G. Geeslin, MD
Updates on Regulatory Issues for Clinical Use of Biologics Andrew G. Geeslin, MD Pre-Course: The Use of Biologics to Treat Sports Medicine Pathology June 3, 2017 11th Biennial ISAKOS Congress 2017, Shanghai,
More informationRegulatory Considerations for Human Cell, Tissues, and Cellular and Tissue- Based Products: Minimal Manipulation and Homologous Use
Regulatory Considerations for Human Cell, Tissues, and Cellular and Tissue- Based Products: Minimal Manipulation and Homologous Use Guidance for Industry and Food and Drug Administration Staff For questions
More informationReporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc.
Reporting Deviations of Biological Products and HCT/Ps Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Relevant Legislation Public Health Service (PHS) Act Regulates biological products
More informationMartha A Wells, MPH Division of Human Tissues OCTGT, CBER, FDA. Pharma Conference HCT/P Meeting January 24, 2007 San Antonio, TX
Guidance for Industry: Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered From Donors Who Were Tested For Communicable Diseases Using Pooled Specimens or Diagnostic
More informationStem Cell Therapy for Wound Healing in Diabetic Limb
Stem Cell Therapy for Wound Healing in Diabetic Limb Tanom Bunaprasert M.D. EC-ATMPs ( EC- Advanced Therapy Medicinal Products) Chulalongkorn Hospital Authority of Laws Public Health Safety act (
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Thomas E. Young,
More informationFDA: The New Animal Drug Approval Process and Cell Based Products
FDA: The New Animal Drug Approval Process and Cell Based Products Lynne Boxer, DVM March 29, 2017 Division of Therapeutic Drugs for Non Food Animals Office of New Animal Drug Evaluation Center for Veterinary
More information3/17/2017. Scope. Guidance 218: Cell Based Products for Animal Use. FDA: The New Animal Drug Approval Process and Cell Based Products
FDA: The New Animal Drug Approval Process and Cell Based Products Lynne Boxer, DVM March 29, 2017 Division of Therapeutic Drugs for Non Food Animals Office of New Animal Drug Evaluation Center for Veterinary
More informationSafa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues. Pharma Conference February
Safa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues Pharma Conference February 2017 1 Background HCT/P regulatory framework Definitions & exceptions Establishment registration-
More informationCBER Regulation of Devices for Cell Therapy
CBER Regulation of Devices for Cell Therapy Richard D. McFarland, Ph.D., M.D. Associate Director for Policy Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and Research Food
More informationDiscover TruPRP. PRP the way you want it.
Discover TruPRP PRP the way you want it. Discover TruPRP Discover the quality of Magellan TruPRP. The Magellan technology provides an automated dual spin processing system that can deliver (PRP) Platelet
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationUDI Guidance Document for Medical Devices Containing HCT/P
LEARNING UDI COMMUNITY UDI Guidance Document for Medical Devices Containing HCT/P WWW.AHRMM.ORG / LUC INTRODUCTION: Human cells, tissues, or cellular or tissue-based products (HCT/Ps) are a precious resource
More informationDevelopment of Regenerative Medicine Products: FDA Perspectives
資料 3-3 Development of Regenerative Medicine Products: FDA Perspectives Steven R. Bauer, Ph.D. Chief, Cellular and Tissue Therapies Branch Office of Cellular, Tissue and Gene Therapies Center for Biologics
More informationHuman Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia
TITLE / DESCRIPTION: DEPARTMENT: Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia Surgical Services PERSONNEL:
More informationRegenerative Medicine and the Changing Regulatory Landscape
Regenerative Medicine and the Changing Regulatory Landscape May 3, 2018 Anne Marie Polak Leavitt Partners Gene Therapy CRISPR-Cas9 Inspired by genetic defense mechanisms found in bacteria Cas9 is an enzyme
More informationRegulatory Issues in Human Subjects Research
Regulatory Issues in Human Subjects Research Ian McNiece, PhD University of Miami Human Subjects Research Require IRB approval Studies of new drugs or applications of drugs require an FDA approved IND
More informationSpecial Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D.
The new england journal of medicine Special Report Balancing Safety and Innovation for Cell-Based Regenerative Medicine Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. Regenerative medicine is a field
More informationSharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016
Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY June 7, 2016 1 Brief description of the Mount Sinai Cellular Therapy Laboratory Overview of BM transplant
More informationHow You Can Use Stem Cells
How You Can Use Stem Cells Dr. Ralph T Bright Macquarie Cosmetic Medicine 21B Bathurst Street Liverpool NSW 2170 www.cosmeticmedicine.com.au (02) 9824 3044 Stem Cell Transfer Many of the people in this
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation
More informationYOUR OWN LIFE
YOUR OWN LIFE Stromal Tissue (ST), a Regenerative Source There is a worldwide consensus that the isolation and collection of regenerative Mesenchymal Stem Cells (MSC s) from differentiated body tissues
More informationCase 0:18-cv UU Document 1 Entered on FLSD Docket 05/09/2018 Page 1 of 17
Case 0:18-cv-61047-UU Document 1 Entered on FLSD Docket 05/09/2018 Page 1 of 17 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA FT. LAUDERDALE DIVISION CASE NO.: 18-CV-61047 UNITED STATES OF
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal
More informationUNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Massachusetts Institute of Technology Harvard Medical School Brigham and Women s Hospital VA Boston Healthcare System 2.79J/3.96J/20.441/HST522J UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE
More information2015-Tissue Bank Processing
2015-Tissue Bank Processing Form Approved OMB No. 0990-0457 Exp. Date 06/30/2020 Welcome to the 2015 Tissue Processing survey. Please refer to the following instructions as you complete this section of
More informationStem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
More information2015-Tissue Storage. Welcome to the 2015 Tissue Storage survey. Please refer to the following instructions as you complete this section of the survey.
2015-Tissue Storage Form Approved OMB No. 0990-0457 Exp. Date 06/30/2020 Welcome to the 2015 Tissue Storage survey. Please refer to the following instructions as you complete this section of the survey.
More informationRegulation of advanced blood cell therapies
Regulation of advanced blood cell therapies www.pei.de Clinical trials using cell-based products Substantially manipulated cells and cells for non-homologous use Quality, safety and non-clinical aspects
More informationStem Cells: Evidence for Efficacy
Stem Cells: Evidence for Efficacy Disclosures VA RR&D 1IK2RX001476-01A1 (PI: Harvey Smith) VA RR&D I01 RX002274 (PI: Harvey Smith) Department of Veterans Affairs Medical Center, Philadelphia, PA FDA Orthopaedic
More informationRegulation of Cell and Gene Therapy Products in Canada
Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and
More informationNanosystems in regenerative medicine. Jöns Hilborn Materials Chemistry The Ångström Laboratory Uppsala University Sweden
Nanosystems in regenerative medicine Jöns Hilborn Materials Chemistry The Ångström Laboratory Uppsala University Sweden Outline Motivation for tissue regeneration Cell based approaches Material based
More informationRegulatory science insights into cellular products and practical microscale technologies for their assessment
Regulatory science insights into cellular products and practical microscale technologies for their assessment Kyung Sung Johnny Lam November 9, 2018 Cellular and Tissue Therapies Branch Division of Cellular
More informationDisclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
More informationEMA s role & responsibility for the development of modern/advanced therapies
EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory
More informationStem Cells 101. Christopher Centeno, M.D. The Centeno-Schultz Clinic Colorado, USA
Stem Cells 101 Christopher Centeno, M.D. The Centeno-Schultz Clinic Colorado, USA My background Began using stem cells to treat orthopedic conditions in 2005 Have published 16 peer reviewed publications
More informationThe Ultimate Guide To STEM CELL THERAPY. for Joint Disorders
The Ultimate Guide To STEM CELL THERAPY for Joint Disorders Who Are We? The Regenerative Orthopedic Clinic is a state-of-the-art medical facility that offers a number of services for non-surgical joint
More informationFDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA
FDA Update Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA 13 th Annual FDA and the Changing Paradigm for HCT/P Regulation February 13, 2017
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More informationRegulation of Biologics in The United States: From a Rich Tradition To A Challenging Future
Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future Chris Joneckis,, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Food and Drug
More informationproducts, or medical devices that will need to come into compliance with premarket approval requirements over the next three years.
Executive Summary Products derived from human tissue have been used as therapeutic products for more than a hundred years. In recent years, human tissue products have been increasingly linked with the
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationQuality Program: Supplies and Reagents
Quality Program: Supplies and Reagents J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ) Supervisor, Quality Assurance and Regulatory Affairs Department of Transfusion Medicine, Clinical Center, NIH Disclosures:
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationBUILT TO CONCENTRATE. Magellan is an autologous concentration system that delivers concentrated platelets and cells at the point of care.
BUILT TO CONCENTRATE Magellan is an autologous concentration system that delivers concentrated platelets and cells at the point of care. DELIVER PERSONALIZED MEDICINE Every patient has a unique biology
More informationInvestor Presentation
Investor Presentation December 2013 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
More informationRegulatory Perspectives of Japan
International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives
More informationRegulatory framework for Stem Cell and Products review in India. Presentation By: Dr. V G Somani Joint Drugs Controller (India) CDSCO (HQ)
Regulatory framework for Stem Cell and Products review in India Presentation By: Dr. V G Somani Joint Drugs Controller (India) CDSCO (HQ) 1 Outline of Presentation Legal Provisions MCI Code of Ethics regulation
More informationAndrew Finnerty General Manager - CCMI
Andrew Finnerty General Manager - CCMI Manufacturing Human Mesenchymal Stem Cells for Clinical Trials Quality Considerations Biopharma and Pharma RQA Regional Forum Bioclin Laboratories, Athlone 13 May
More informationCell and Gene Therapy Medicinal Product Management Act (Draft) General Information
Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information July 2017 At present there are still many diseases that cannot be cured by current medical technology and existing chemical
More informationCANADA (HEALTH CANADA)
LEADERS 1 THE GMP GAZETTE TM February 2015 HPFBI CANADA (HEALTH CANADA) Blood Establishment Registration Application: Form and Instructions - (FRM-0353) Who s affected? Anyone who plans to perform the
More informationRegenerative Medicine and Stem Cell Therapies
Regenerative Medicine and Stem Cell Therapies Regenerative Medicine Major component of successful regenerated / tissue engineered organs Scaffolds A critical element is the binding of the repopulating
More informationAdult Stem Cells for Chronic Pain. Dr. John Hughes, DO January 24 th, 2018
Adult Stem Cells for Chronic Pain Dr. John Hughes, DO January 24 th, 2018 Dr. John Hughes, DO Doctor of Osteopathy From Georgia Arizona College of Osteopathic Medicine - 2007 Aspen Integrative Medicine
More informationIS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing Practice PHS Act: : Public Health Service Act CFR: : Code of Federal Regulations CP: : Comp
PREPARING FOR AN FDA INSPECTION August 11, 2011 Kip J. Hanks, Investigator Biologics National Expert FDA Division of Domestic Field Investigations 1 IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing
More informationRegulating Cell Therapy: An Ex-Regulators Perspective
Regulating Cell Therapy: An Ex-Regulators Perspective Christopher A Bravery 1 Introduction Regulation of Healthcare products in the EU What is cell therapy? How does it fit into existing framework? Is
More informationInspection of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
COMPLIANCE PROGRAM GUIDANCE MANUAL Inspection of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) 7341.002 Implementation Date: Completion Date: when posted on-going Program/Assignment
More informationDistinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Distinguishing Medical Device Recalls from Product Enhancements and Associated Reporting Requirements Draft Guidance for Industry
More informationINTRODUCTION OF BIOCELLULAR REGENERATIVE MEDICINE
Evolution of Cell-Based Therapies Over the past decade, great strides have been made in the understanding and potentials of guided cell-based therapies. As an evolving expansion of palpation guided injection
More informationTISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS
TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS HLC101B August 2014 Yojana Jeevane Project Analyst ISBN: 1-56965-894-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationRegulatory requirements for cell based medicinal products
Regulatory requirements for cell based medicinal products 資料 3-2 Committee 25 August 2010 Dr. Bettina Klug, MSc Paul-Ehrlich-Institut, Langen klube@pei.de Paul-Ehrlich-Institut Federal Institute for Vaccines
More informationThe FDA/CDRH Perspective in the Regulation of Surgical Mesh
The FDA/CDRH Perspective in the Regulation of Surgical Mesh David Krause, Ph.D., Branch Chief Plastic & Reconstructive Surgery Branch Division of Surgical, Orthopedic & Restorative Devices Office of Device
More informationDiscover TruPRP. PRP the way you want it.
Discover TruPRP PRP the way you want it. Discover TruPRP Discover the quality of Magellan TruPRP. The Magellan technology provides an automated dual spin processing system that can deliver (PRP) Platelet
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More informationRegulatory Updates on Cellular Therapy Products in Japan
Regulatory Updates on Cellular Therapy Products in Japan Tetsuya Kusakabe, Ph.D., M.P.H. Review Director Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA),
More informationFDA Inspections: FDA Inspections: An Overview Overview
FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an
More informationINTRODUCTION. How we regulate Cell and Gene Therapy Product? Presented by Azizah Ab Ghani National Pharmaceutical Control Bureau
INTRODUCTION How we regulate Cell and Gene Therapy Product? Presented by Azizah Ab Ghani National Pharmaceutical Control Bureau 1 CGTP Multidisciplinary approach MOH Medical Development Division Medical
More informationRegenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016
Regenerative Medicine Halland Chen, MD Speaker Disclosures I disclose that I am not a consultant or have any financial interests. 2 What is regenerative medicine? Regeneration of human cells, tissues,
More informationInstructions for Use READY TO USE
READY TO USE Instructions for Use LifeCell Corporation One Millennium Way Branchburg, NJ 08876-3876 1.908.947.1215 1.800.367.5737 Fax: 1.908.947.1089 E-mail: customerservicegroup@lifecell.com www.lifecell.com
More information2012-Tissue Distribution
2012-Tissue Distribution Form Approved OMB. 0990-0457 Exp. Date 06/30/2020 Welcome to the 2012 Tissue Distribution survey. Please refer to the following instructions as you complete this section of the
More informationUNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA EASTERN DIVISION
Case :-cv-00-jgb-kk Document Filed 0/0/ Page of Page ID #: 0 CHAD A. READLER Acting Assistant Attorney General GUSTAV W. EYLER Acting Director Consumer Protection Branch NATALIE N. SANDERS Trial Attorney
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationA Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products
A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More informationSpecial Issue. Mesoblast Limited
Overview is an Australian biotechnology company committed to the commercialization of novel treatments for orthopedic conditions by using its unique adult stem cell technology for the regeneration and
More informationOverview. A brief from
A brief from Dec 2017 Getty Images What Are Compounded Drugs, and How Can They Be Kept Safe? Drug Quality and Security Act plays key role in important but potentially high-risk aspect of health care Overview
More informationFDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies
ADVISORY February 2011 FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies Contacts On February 15, 2011, the U.S. Food and Drug Administration
More informationAll contents herein are the sole property of MEDIPOST Co., Ltd. Any reproduction or distribution of this document without the written consent of
All contents herein are the sole property of MEDIPOST Co., Ltd. Any reproduction or distribution of this document without the written consent of MEDIPOST Co., Ltd is prohibited. Copyright c 2004-2011 MEDIPOST.
More informationASX Small to Mid Caps Conference Singapore. May 27 th, 2010
ASX Small to Mid Caps Conference Singapore May 27 th, 2010 Mesoblast Capital Overview Fund Raisings $m IPO @ 50 cents 21.0 Equity Placements: Jul-06 17.4 Dec-07 13.4 Apr-09 10.8 May-10 37.0 Option funds
More informationHCT/P Deviations & Reporting. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017
HCT/P Deviations & Reporting CASE STUDIES FROM TISSUE AND EYE BANKS AND CELLULAR THERAPY. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017 Tissue Bank Perspective Ashley
More information20 years. Healed! What did he say? Just got home from the doctor. How s Dad?
2 0 1 2 A N N U A L R E P O R T How s Dad? Just got home from the doctor. What did he say? Healed! 20 years of stem cell research, development, and global leadership distilled into the only word that matters
More informationRegulation of Microbiota- Based Products
Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal
More informationGuidance for Industry and FDA:
1227 25th St., NW Washington, DC 20037-1156 Guidance for Industry and FDA: Application of cgmp Regulations to Combination Products: Frequently Asked Questions PROPOSED GUIDANCE January 15, 2007 This guidance
More informationDrug /Device Combinations: The Convergence of Pharmaceutical and Biomaterial Science
Drug /Device Combinations: The Convergence of Pharmaceutical and Biomaterial Science Are We Just Raising the Stakes for Industry, Regulators, and Decision Makers? David Ames Director, Health Economics
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance
More informationProcessed from Donated Human Tissue by LifeCell Corporation for KCI USA, Inc.
for wounds instructions for use Processed from Donated Human Tissue by LifeCell Corporation for KCI USA, Inc. marketed by KCI USA, Inc. San Antonio, TX 78219 USA 800.275.4524 www.kci1.com www.graftjacketbykci.com
More informationT H E R A P Y REGENERATIVE MEDICINE NATURAL EFFECTIVE LIFE-CHANGING
S T E M C E L L T H E R A P Y REGENERATIVE MEDICINE NATURAL EFFECTIVE LIFE-CHANGING STEM CELL THERAPY Early stem cell research has traditionally been associated with the controversial use of embryonic
More informationCell Therapy Liaison Meeting, June 16, 2006
Cell Therapy Liaison Meeting, June 16, 2006 Host Organization Original Agenda Moderator: Stephen J. Noga, MD, PhD 1:00-1:15 Call to Order and Introduction of agenda and meeting participants Review of Summary
More informationImporting/Exporting Conventional HCT/Ps
Importing/Exporting Conventional HCT/Ps ISCT/FDA Liaison Meeting January 4, 2007 Scott A. Brubaker, CTBS American Association of Tissue Banks Conventional Tissue Banks! FDA term from the preamble to the
More informationUS FDA: CMC Issues for INDs
ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research
More informationPlatelet Concentrate in Total Knees BIOLOGICS. This brochure is for International use only. It is not for distribution in the United States.
Platelet Concentrate in Total Knees BIOLOGICS This brochure is for International use only. It is not for distribution in the United States. Platelet Concentrate in Total Knees Total Knee Arthroplasty Total
More information